LAVA Therapeutics NV [NASDAQ: LVTX] stock went on an upward path that rose over 1.29% on Friday, amounting to a one-week price increase of more than 2.61%.
Over the last 12 months, LVTX stock rose by 65.09%. The one-year LAVA Therapeutics NV stock forecast points to a potential downside of -14.6. The average equity rating for LVTX stock is currently 3.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $41.30 million, with 26.31 million shares outstanding and 13.02 million shares in the current float. Compared to the average trading volume of 90.55K shares, LVTX stock reached a trading volume of 161708 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on LAVA Therapeutics NV [LVTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LVTX shares is $1.37 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LVTX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for LAVA Therapeutics NV shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on December 12, 2024. The new note on the price target was released on December 11, 2024, representing the official price target for LAVA Therapeutics NV stock. Previously, the target price had yet another raise to $9, while H.C. Wainwright analysts kept a Buy rating on LVTX stock.
The Price to Book ratio for the last quarter was 2.07, with the Price to Cash per share for the same quarter was set at 2.14.
LVTX Stock Performance Analysis:
LAVA Therapeutics NV [LVTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.61. With this latest performance, LVTX shares gained by 3.29% in over the last four-week period, additionally plugging by 21.71% over the last 6 months – not to mention a rise of 65.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LVTX stock in for the last two-week period is set at 62.69, with the RSI for the last a single of trading hit 0.0503, and the three-weeks RSI is set at 0.0672 for LAVA Therapeutics NV [LVTX]. The present Moving Average for the last 50 days of trading for this stock 1.4432, while it was recorded at 1.5400 for the last single week of trading, and 1.2893 for the last 200 days.
Insight into LAVA Therapeutics NV Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and LAVA Therapeutics NV [LVTX] shares currently have an operating margin of -610.66% and a Gross Margin at 123.29%. LAVA Therapeutics NV’s Net Margin is presently recorded at -566.89%.
LAVA Therapeutics NV (LVTX) Capital Structure & Debt Analysis
According to recent financial data for LAVA Therapeutics NV. ( LVTX), the Return on Equity (ROE) stands at -90.07%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -37.02%, reflecting the company’s efficiency in generating profits from its assets. Additionally, LAVA Therapeutics NV’s Return on Invested Capital (ROIC) is -141.90%, showcasing its effectiveness in deploying capital for earnings.
LAVA Therapeutics NV (LVTX) Efficiency & Liquidity Metrics
Based on LAVA Therapeutics NV’s (LVTX) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
LAVA Therapeutics NV (LVTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, LAVA Therapeutics NV. (LVTX) effectively leverages its workforce, generating an average of -$832058.82 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.78% and a Quick Ratio of 10.78%, indicating strong ability to cover short-term liabilities.
LVTX Stock EPS
With the latest financial reports released by the company, LAVA Therapeutics NV posted -0.43/share EPS, while the average EPS was predicted by analysts to be reported at -0.32/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.11. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LVTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for LAVA Therapeutics NV go to 24.31%.
LAVA Therapeutics NV [LVTX] Institutonal Ownership Details
There are presently around $36.39%, or 54.06%% of LVTX stock, in the hands of institutional investors. The top three institutional holders of LVTX stocks are: REDMILE GROUP, LLC with ownership of 2.07 million shares, which is approximately 7.7419%. BRUCE & CO., INC., holding 0.77 million shares of the stock with an approximate value of $$1.39 million in LVTX stocks shares; and BRUCE & CO., INC., currently with $$0.66 million in LVTX stock with ownership which is approximately 1.3719%.
